Skip to main content

UPLC Method for Determination of Moxonidine and Its Degradation Products in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form

Abstract

A simple, rapid, isocratic, stability-indicating reverse phase ultra-performance liquid chromatographic (RP-UPLC) method was developed and validated for the routine analysis of moxonidine in the presence of its degradation products in active pharmaceutical ingredient and pharmaceutical dosage forms. Forced degradation studies were performed according to the guidance of International Conference for Harmonization and were used to evaluate moxonidine intrinsic stability. The drug was subjected to acid, neutral and base hydrolysis as well as to oxidative, thermal and photolytic decomposition in both solution and solid state. The drug appeared to be unstable towards acid and base hydrolysis. To achieve desirable conditions for UPLC analysis, the method development was done with the assistance of experimental design and multivariate optimization methodology by means of Derringer’s desirability function. Stress samples were analyzed according to the experimental plan for fractional factorial screening design and Box-Behnken optimization design. The chromatographic separation was achieved on a C18 Hypersil Gold aq. column (100 mm × 2.1 mm, 1.9 μm) with the mobile phase consisting of methanol–ammonium acetate buffer (10 mM, pH 3.43) mixture (0.9:99.1, v/v) pumped at a flow rate of 870 μL min−1 and detection wavelength of 255 nm. The UPLC–MS and UPLC–MS/MS analyses were further used to characterize the found degradation products. The validation of the proposed method was also performed considering selectivity, linearity, accuracy, precision, limit of detection and limit of quantification, and the results indicated that the method fulfilled all required criteria. The method was successfully applied to the analysis of commercial tablets.

This is a preview of subscription content, access via your institution.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. 1.

    Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P (1996) J Cardiovasc Pharm 27:S26–S37

    CAS  Article  Google Scholar 

  2. 2.

    European Pharmacopoeia, (2011) 7th edn.

  3. 3.

    British Pharmacopoeia (2011)

  4. 4.

    Zhao L, Ding L, Wei X (2006) J Pharm Biomed Anal 40:95–99

    CAS  Article  Google Scholar 

  5. 5.

    Rudolph M, Janssen W, Strassner M (1992) J Pharm Biomed Anal 10:323–328

    CAS  Article  Google Scholar 

  6. 6.

    Milovanović S, Otašević B, Zečević M, Živanović LJ, Protić A (2012) J Pharm Biomed Anal 59:151–156

    Article  Google Scholar 

  7. 7.

    Kakde R, Gadpayale K, Qureshi MO (2012) Int J PharmTech Res 4(1):358–363

    CAS  Google Scholar 

  8. 8.

    ICH topic Q1A(R2) (2003) Stability testing on new drug substances and products. Fed Regist 68:65717–65718

    Google Scholar 

  9. 9.

    Kumar A, Saini G, Nair A, Sharma R (2012) Acta Pol Pharm Drug Res 69:371–380

    CAS  Google Scholar 

  10. 10.

    Brereton RG (2003) Chemometrics—data analysis for the laboratory and chemical plant. Wiley, Chichester

    Google Scholar 

  11. 11.

    Ortiz MC, Herrero A, Sanllorente S, Reguera C (2005) Talanta 65:246–254

    CAS  Google Scholar 

  12. 12.

    Safa F, Hadjmohammadi MR (2005) J Chromatogr A 1078:42–50

    CAS  Article  Google Scholar 

  13. 13.

    Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040

    CAS  Article  Google Scholar 

  14. 14.

    Wren SAC, Tchelitcheff P (2006) J Chromatogr A 1119:140–146

    CAS  Article  Google Scholar 

  15. 15.

    Ferreira SLC, Brun RE, Paranhos da Silva EG, Lopes dos Santos WN, Quintella CM, David JM, Bittencourt de Andrade J, Breitkreitz MC, Jardim ICSF, Neto BB (2007) J Chromatogr A 1158:2–14

    CAS  Article  Google Scholar 

  16. 16.

    ICH topic Q2(R1) (1997) Validation of analytical procedures: text and methodology. Fed Regist 62: 27463–27467 (addendum incorporated 2005)

    Google Scholar 

  17. 17.

    Araujo P (2009) J Chromatogr B 877:2224–2234

    CAS  Article  Google Scholar 

  18. 18.

    Nováková L, Matysová L, Solich P (2006) Talanta 68:908–918

    Article  Google Scholar 

Download references

Acknowledgments

This research was supported by the Ministry of science and technological development of Republic of Serbia as the part of the project no. 172033.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Mira Zečević.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Otašević, B., Milovanović, S., Zečević, M. et al. UPLC Method for Determination of Moxonidine and Its Degradation Products in Active Pharmaceutical Ingredient and Pharmaceutical Dosage Form. Chromatographia 77, 109–118 (2014). https://doi.org/10.1007/s10337-013-2580-x

Download citation

Keywords

  • UPLC
  • Experimental design
  • Multivariate optimization
  • Forced degradation studies
  • Moxonidine